Hematology NewsObinutuzumab provides strong early responses in untreated MCLJune 17, 2019Mantle Cell LymphomaB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology News‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCLJune 17, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsRivaroxaban tied to higher GI bleeding than other NOACsJune 17, 2019GastroenterologyThrombosisBleeding DisordersGastrointestinal Cancer
Oncology PracticeResponse endures in cemiplimab-treated patients with cutaneous SCCJune 14, 2019Nonmelanoma Skin Cancer
Oncology PracticeSkin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse eventsJune 14, 2019Immuno-oncologyImmunotherapy
Oncology PracticeEULAR issues guidelines on managing rheumatic complications of cancer immunotherapiesJune 14, 2019Immuno-oncologyImmunotherapy
Hematology NewsR2 appears active in high-risk FL and MZLJune 14, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular LymphomaRare Diseases
Hematology NewsAntibody hierarchy may drive development of SLE vs. antiphospholipid syndromeJune 14, 2019Thrombosis
Oncology PracticeAdvanced basal cell carcinoma responds to pembrolizumab in proof-of-concept studyJune 13, 2019Nonmelanoma Skin Cancer
Hematology NewsTriplet offers longest PFS yet seen in relapsed/refractory myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Oncology PracticePREDIX HER2 trial: Similar efficacy, less toxicity with T-DM1 for HER2+, HR+ breast cancerJune 12, 2019Breast Cancer
